>
Company >
History
-
2023
-
Feb.
Obtainment of the patents for 2 types of WRS biomarker-specific binding antibodies
-
Feb.
Secured a initial production contract and global distribution rights of ‘JWELICS Q6’
-
Jan.
Signed a transfer contract of the rights to 12 nutritional infusion solutions
-
Jan.
Signed a transfer contract of the medical device business unit with JW Pharmaceutical
-
2022
-
Feb.
Signed the MOU with Micro-Digital for high-sensitivity on-site diagnostic analyzer ‘JWELICS Q6’
-
2021
-
Sep.
Signed a non-cxclusive license agreement with Immunovia(Sweden) for the patent 'diagnostic biomarker of pancreatic cancer'
-
Aug.
World's 1st Europeon&Chinese patent registration of diagnostic technique for sepsis
-
Jan.
Equity invesrment to 'Onebiomed', a Singapore molecular diagnostic company
-
2020
-
Dec.
Merged as a subsidiary in JW Life-Science
-
Feb.
Obtainment of a US patent for an early diagnosis technology of pancreatic cancer
-
Jul.
Obtainment of the patents for a diagnosis technology of septicemia both in US and Japan
-
2019
-
Oct.
Exclusive supply contract with JEOL biochemical equipment
-
2018
-
Nov.
Launched SANGRAY, the first X-ray blood irradiator in Korea
-
Sep.
Released steam sterilizers JW-SS360, JW-SS270
-
Mar.
Early detection of pancreatic cancer "Multiple biomarker diagnostic kit" Technology transfer contract signed (Yonsei University)
-
2016
-
May.
Signed a contract for early diagnosis of sepsis infection technology transfer ((Re)Pharmaceutical Bioconvergence Research Group)
-
Apr.
Established JW Bioscience
